Is it possible to predict BCG effectivity in the treatment of superficial bladder cancer? Are there any markers?
Küçük Resim Yok
Tarih
2012
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Yayincilik
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: Bacillus Calmette-Guerin (BCG) is a standard treatment for reducing tumour recurrence and delaying progression of highrisk, non-muscle-invasive bladder tumours. However, it is not clear yet which patients are more likely to be responders to BCG. New Findings: The host factors and the tumor characteristics failed to be an independent factor in the prediction of BCG affectivity in the treatment of non-muscle invasive bladder cancer. The local immune response after intravesical BCG installation was studied meticulously and the predictive value of the elements in this pathway was determined. Among these urine levels of IL-2 has most encouraging results and also the determination of nucleotide polymorphisms of different cytokines in the inflammatory pathway seem promising. Results: Research continues to determine which patients would benefit from BCG treatment and also to establish a better outcome. New approaches are needed in the light of developments in biomedical technology. A very critical part of this therapy is to find out the correlation of different cytokines with BCG therapy, which will give a better insight not only the mechanism but also a better therapeutic options.
Açıklama
Anahtar Kelimeler
Bacillus Calmette-Guerin, Bladder Cancer, Prognosis
Kaynak
Uroonkoloji Bulteni-Bulletin of Urooncology
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
11
Sayı
1
